Healthdatamanagement | Jan 2, 2018
The Food and Drug Administration has approved Arterys’ web-based imaging analytics platform, which marries cloud-based supercomputing and artificial intelligence, for clinical use.
The FDA approval allows the Arterys product, called MICA, to supply clinical guidance to clinicians treating cardiac patients. The company is awaiting FDA clearance that would allow the platform to be used by oncology teams treating patients with lung and liver conditions.
“The Arterys MICA platform realizes our vision of democratizing high-quality care via data-driven medicine and assisting radiologists across a wide variety of workflows,” said CEO and co-founder Fabien Beckers. “The platform and these products get us one step closer to our vision of empowering physicians with AI to convert data into insights so they can define the optimal path for each of their patients.”
The company says MICA can support multiple workflows in a variety of imaging modalities, such as MRI and CT. It was designed to work seamlessly with applications that integrate AI algorithms into workflows, enabling clinicians to interact with and edit their output in real time. The system also captures these user edits, so that algorithms can later be improved based on real-world use, creating collective intelligence that can benefit all users.